FDA Clearance Tracker · P170002-S030
RHA®3 dermal filler
Last checked: Nov 20, 2026Latest source record: Oct 27, 2023 (this decision)Source: openFDAMethods & limitations
Decided
Oct 27, 2023
Approved
Time to decision
179 days
Received May 1, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P170002-S030
- Device name
- RHA®3 dermal filler
- Applicant
- Teoxane S.A.
- Applicant location
- Geneva
- Received
- May 1, 2023
- Decided
- Oct 27, 2023
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P170002
Device type
- Device type
- Implant, dermal, for aesthetic use (LMH)
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for RHA®3 for expanding the indications to include injection in the vermillion body, vermillion border and oral commissures to achieve lip augmentation and lip fullness in adults aged 22 years or older. RHA®3 is also indicated for injection into the mid-to-deep dermis for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds (NLF), in adults aged 22 years or older.
Source documents
Other decisions for Teoxane S.A.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- RHA Redensity® Eye Lido; RHA Redensity® EyePMA supplement
P170002-S050 · Decided May 12, 2026 · 256 days after receipt · Panel Track
Device type: Implant, dermal, for aesthetic use (LMH) · General & Plastic Surgery
- RHA® Dynamic Volume, RHA®4PMA supplement
P170002-S048 · Decided Sep 18, 2025 · 290 days after receipt · Panel Track
Device type: Implant, dermal, for aesthetic use (LMH) · General & Plastic Surgery
- RHA® Redensity Mepi, RHA®2 Mepi, RHA®3 Mepi, RHA®4 MepiPMA supplement
P170002-S026 · Decided Oct 13, 2023 · 240 days after receipt · Panel Track
Device type: Implant, dermal, for aesthetic use (LMH) · General & Plastic Surgery
2 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.